Biotechnology Analysts Schmidt, Bienkowski & Brayer, along with Dr. Kevin Kuo, Clinician-Investigator and Clinical Lead of Red Blood Cell Disorder Program at University Health Network, discuss novel therapies for Thalassemia and Sickle Cell Disorder (blue‘>AGIO, BLUE, CRSP, NVO and VRTX) on an Analyst/Industry conference call to be held on March 14 at 1 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AGIO:
- Biotech Alert: Searches spiking for these stocks today
- Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Agios Pharmaceuticals reports 2023 EPS ($6.33), consensus ($6.26)
- AGIO Earnings this Week: How Will it Perform?
- Agios Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
